1065 related articles for article (PubMed ID: 25822366)
21. ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.
Zhu L; Li Q; Wong SH; Huang M; Klein BJ; Shen J; Ikenouye L; Onishi M; Schneidawind D; Buechele C; Hansen L; Duque-Afonso J; Zhu F; Martin GM; Gozani O; Majeti R; Kutateladze TG; Cleary ML
Cancer Discov; 2016 Jul; 6(7):770-83. PubMed ID: 27154821
[TBL] [Abstract][Full Text] [Related]
22. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
Liu W; Deng L; Song Y; Redell M
PLoS One; 2014; 9(5):e98270. PubMed ID: 24858818
[TBL] [Abstract][Full Text] [Related]
23. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.
Daigle SR; Olhava EJ; Therkelsen CA; Majer CR; Sneeringer CJ; Song J; Johnston LD; Scott MP; Smith JJ; Xiao Y; Jin L; Kuntz KW; Chesworth R; Moyer MP; Bernt KM; Tseng JC; Kung AL; Armstrong SA; Copeland RA; Richon VM; Pollock RM
Cancer Cell; 2011 Jul; 20(1):53-65. PubMed ID: 21741596
[TBL] [Abstract][Full Text] [Related]
24. DOT1L activity in leukemia cells requires interaction with ubiquitylated H2B that promotes productive nucleosome binding.
Spangler CJ; Yadav SP; Li D; Geil CN; Smith CB; Wang GG; Lee TH; McGinty RK
Cell Rep; 2022 Feb; 38(7):110369. PubMed ID: 35172132
[TBL] [Abstract][Full Text] [Related]
25. Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia.
Barve A; Vega A; Shah PP; Ghare S; Casson L; Wunderlich M; Siskind LJ; Beverly LJ
Cells; 2019 Oct; 8(11):. PubMed ID: 31717699
[TBL] [Abstract][Full Text] [Related]
26. The emerging roles of DOT1L in leukemia and normal development.
McLean CM; Karemaker ID; van Leeuwen F
Leukemia; 2014 Nov; 28(11):2131-8. PubMed ID: 24854991
[TBL] [Abstract][Full Text] [Related]
27. The stem cell factor SALL4 is an essential transcriptional regulator in mixed lineage leukemia-rearranged leukemogenesis.
Yang L; Liu L; Gao H; Pinnamaneni JP; Sanagasetti D; Singh VP; Wang K; Mathison M; Zhang Q; Chen F; Mo Q; Rosengart T; Yang J
J Hematol Oncol; 2017 Oct; 10(1):159. PubMed ID: 28974232
[TBL] [Abstract][Full Text] [Related]
28. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
Daigle SR; Olhava EJ; Therkelsen CA; Basavapathruni A; Jin L; Boriack-Sjodin PA; Allain CJ; Klaus CR; Raimondi A; Scott MP; Waters NJ; Chesworth R; Moyer MP; Copeland RA; Richon VM; Pollock RM
Blood; 2013 Aug; 122(6):1017-25. PubMed ID: 23801631
[TBL] [Abstract][Full Text] [Related]
29. Harnessing gene repression to inhibit leukemia.
Harte PJ; Ernst P
Nat Med; 2015 Apr; 21(4):308-10. PubMed ID: 25849269
[No Abstract] [Full Text] [Related]
30. Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
Kaushik S; Liu F; Veazey KJ; Gao G; Das P; Neves LF; Lin K; Zhong Y; Lu Y; Giuliani V; Bedford MT; Nimer SD; Santos MA
Leukemia; 2018 Feb; 32(2):499-509. PubMed ID: 28663579
[TBL] [Abstract][Full Text] [Related]
31. Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia.
Richter WF; Shah RN; Ruthenburg AJ
Elife; 2021 Jul; 10():. PubMed ID: 34263728
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in
Campbell CT; Haladyna JN; Drubin DA; Thomson TM; Maria MJ; Yamauchi T; Waters NJ; Olhava EJ; Pollock RM; Smith JJ; Copeland RA; Blakemore SJ; Bernt KM; Daigle SR
Mol Cancer Ther; 2017 Aug; 16(8):1669-1679. PubMed ID: 28428443
[TBL] [Abstract][Full Text] [Related]
33. Functional interdependence of BRD4 and DOT1L in MLL leukemia.
Gilan O; Lam EY; Becher I; Lugo D; Cannizzaro E; Joberty G; Ward A; Wiese M; Fong CY; Ftouni S; Tyler D; Stanley K; MacPherson L; Weng CF; Chan YC; Ghisi M; Smil D; Carpenter C; Brown P; Garton N; Blewitt ME; Bannister AJ; Kouzarides T; Huntly BJ; Johnstone RW; Drewes G; Dawson SJ; Arrowsmith CH; Grandi P; Prinjha RK; Dawson MA
Nat Struct Mol Biol; 2016 Jul; 23(7):673-81. PubMed ID: 27294782
[TBL] [Abstract][Full Text] [Related]
34. Disordered epigenetic regulation in MLL-related leukemia.
Zhang Y; Chen A; Yan XM; Huang G
Int J Hematol; 2012 Oct; 96(4):428-37. PubMed ID: 23054645
[TBL] [Abstract][Full Text] [Related]
35. Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.
Shen C; Jo SY; Liao C; Hess JL; Nikolovska-Coleska Z
J Biol Chem; 2013 Oct; 288(42):30585-30596. PubMed ID: 23996074
[TBL] [Abstract][Full Text] [Related]
36. DOT1L O-GlcNAcylation promotes its protein stability and MLL-fusion leukemia cell proliferation.
Song T; Zou Q; Yan Y; Lv S; Li N; Zhao X; Ma X; Liu H; Tang B; Sun L
Cell Rep; 2021 Sep; 36(12):109739. PubMed ID: 34551297
[TBL] [Abstract][Full Text] [Related]
37. Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential.
Kuntimaddi A; Achille NJ; Thorpe J; Lokken AA; Singh R; Hemenway CS; Adli M; Zeleznik-Le NJ; Bushweller JH
Cell Rep; 2015 May; 11(5):808-20. PubMed ID: 25921540
[TBL] [Abstract][Full Text] [Related]
38. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
39. Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia.
Chen L; Sun Y; Wang J; Jiang H; Muntean AG
Oncotarget; 2016 May; 7(18):25208-23. PubMed ID: 27007052
[TBL] [Abstract][Full Text] [Related]
40. Computer-Aided Discovery of Massonianoside B as a Novel Selective DOT1L Inhibitor.
Chen J; Park HJ
ACS Chem Biol; 2019 May; 14(5):873-881. PubMed ID: 30951287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]